

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management

Alan Kaplan,^{1*} J. Mark FitzGerald,² Roland Buhl,³ Christian Vogelberg,⁴ Eckard Hamelmann⁵

¹Family Physician Airways Group of Canada, University of Toronto, Toronto, ON, Canada; ²Centre for Heart and Lung Health, Vancouver, BC, Canada; ³Pulmonary Department, Johannes Gutenberg University Mainz, Mainz, Germany; ⁴Department of Pediatric Pulmonology and Allergy, University Hospital Carl Gustav Carus, Technical University of Dresden, Dresden, Germany; ⁵Klinik für Kinder und Jugendmedizin, Evangelisches Klinikum Bethel, Bielefeld, and Allergy Center of the Ruhr University, Bochum, Germany

SUPPLEMENTARY METHODS

Search strings

Studies of LABA as add-on to ICS

```
(((((((((clinical trial[MeSH Terms]) OR clinical trial) OR clinical study))))))
AND asthma[MeSH Terms]))
AND (((((((((Asthma Control Questionnaire) OR ACQ)) OR ((forced expiratory volume) OR FEV))
OR ((exacerbation) OR worsening)) OR adverse event))))
AND ((((((((((seretide) OR symbicort) OR advair) OR viani) OR flutiform))
OR ((((((((((glucocorticoids[MeSH Terms]) OR inhaled corticosteroid*) OR budesonide) OR
beclomethasone) OR beclometasone) OR fluticasone) OR triamcinolone) OR flunisolide) OR
ciclesonide)) AND ((((((((((adrenergic beta 2 receptor antagonists[MeSH Terms]) OR (((beta*) AND
agonist*)) AND ((long-acting) OR "long acting")) OR (((beta*) AND adrenergic*)) AND ((long-acting)
OR "long acting")) OR ((bronchodilat*) AND ((long-acting) OR "long acting")) OR salmeterol) OR
serevent) OR *formoterol) OR foradil) OR vilanterol))))))
AND ("2015/05/01"[Date - Publication]: "2020/02/19"[Date - Publication])
```

Studies of LTRA as add-on to ICS

(((((((((clinical trial[MeSH Terms]) OR clinical trial) OR clinical study))))))

AND asthma[MeSH Terms]))

AND (((((((((Asthma Control Questionnaire) OR ACQ)) OR ((forced expiratory volume) OR FEV))

OR ((exacerbation) OR worsening)) OR adverse event))))

AND (((((((((((glucocorticoids[MeSH Terms]) OR inhaled corticosteroid*) OR budesonide) OR
beclomethasone) OR beclometasone) OR fluticasone) OR triamcinolone) OR flunisolide) OR
ciclesonide))) AND (((((((((((leukotriene antagonists[MeSH Terms]) OR LTRA) OR leukotriene*)
OR leukotriene*) OR anti-leukotriene*) OR anti-leucotriene*) OR montelukast) OR singulair)
OR zafirlukast) OR accolate) OR pranlukast) OR azlaire))))

AND ("2013/01/01"[Date - Publication] : "2020/02/19"[Date - Publication])

Studies of LAMA as add-on to ICS

(((((((((clinical trial[MeSH Terms]) OR clinical trial) OR clinical study))))))

AND asthma[MeSH Terms]))

AND (((((((((Asthma Control Questionnaire) OR ACQ)) OR ((forced expiratory volume) OR FEV))

OR ((exacerbation) OR worsening)) OR adverse event))))

AND (((((((((((glucocorticoids[MeSH Terms]) OR inhaled corticosteroid*) OR budesonide) OR
beclomethasone) OR beclometasone) OR fluticasone) OR triamcinolone) OR flunisolide) OR
ciclesonide))) AND (((((((((((((((((((muscarinic) AND antagonist*)) AND (((long-acting) OR
"long acting")))))))) OR ((antagonists, muscarinic[MeSH Terms]) AND (((long-acting) OR "long
acting")))))))) OR LAMA) OR glycopyrronium) OR aclidinium) OR tiotropium) OR umeclidinium)
OR NVA237) OR seebri) OR LAS34273) OR turdorza) OR pressair) OR eklira) OR genuair) OR
spiriva) OR GSK573719))))

AND ("2015/05/01"[Date - Publication] : "2020/02/19"[Date - Publication])